Thomas T. Tibbitts, Ph. D. founded DTI in May 2020 to integrate the latest technologies in genomics, biology and computing to bring new medicines to patients suffering with respiratory infections and diseases of the lung. Dr. Tibbitts, serving as its CEO and Head of Research and Development, has over twenty years experience in the pharmaceutical industry. Most recently, Dr. Tibbitts served as Senior Vice President for Computational Research at Goldfinch Bio, where he launched the Kidney Genome Atlas and built a world-class team for sequencing thousands of patients and integrating transcriptomics and epigenetics for the discovery of novel genetic targets in kidney disease. He was part of the initial team that launched Goldfinch with $55M series A funding in 2016 at Third Rock Ventures. At Infinity Pharmaceuticals, Thomas contributed to multiple drug programs for over a decade which lead to Copiktra (duvelisib), a medication approved to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) and IPI-549, currently in clinical development for the treatment of advanced urothelial cancer. Dr. Tibbitts holds a PhD in Biophysics from Brandeis University and has numerous patents and peer-reviewed publications in drug discovery, oncology, enzymology and structural biology.
Thomas Tibbitts
Wendy Rieder
Wendy Rieder, a seasoned business professional with 20+ years experience in biotech, pharmaceutical, medical device and related industries, leading Intellectual property, corporate legal, compliance, regulatory affairs and business development in start-ups to large corporations. General Counsel, Secretary and Sr. Vice President, Legal and Intellectual Property for Synta Pharmaceuticals Corp., a NASDAQ-listed pharma company developing innovative drugs for cancer and inflammatory diseases. Wendy was with Synta from start up in 2002 through a reverse merger with Madrigal Pharmaceuticals in 2016. A core member of IPO team in 2007 and the lead attorney for Synta's two separate $1B+ transactions with major pharmaceutical company partners. Co-founded Microbiotix, Inc., a privately-held pharmaceutical company focused on developing anti-infective agents. Earlier at Boehringer Ingelheim Pharmaceuticals, Inc. and Fish & Neave (now Ropes & Grey). Bachelors degree in chemistry, magna cum laude, from Barnard College, Masters degree in organic chemistry from Columbia University and a juris doctor degree from Fordham University School of Law. Certified Compliance and Ethics Professional (CCEP), registered US patent attorney and licensed to practice law in New York, Connecticut, Massachusetts, and Washington, DC.
Diego Borges-Rivera
Diego Borges-Rivera, M. Sc, 10+ years of experience using R, Python, and Unix analyzing huge volumes of biologically derived sequencing data using almost any hardware, from high performance cloud computing clusters to tiny system on chip devices. Deep biological understanding of eukaryotic 3D gene architecture and regulation.
Extensive experience with cancer genomics and non-coding regulatory elements driving oncogenesis. Ability to tie together disparate biologically derived databases in order to construct novel hypothesis.
Diego built and implemented a large part of the computational backend for DTI.
Assembling the team is currently underway
We are in the process of building a world-class research team with skills in molecular biology, preclinical development, statistical genetics, computational biology, bioinformatics, bio-molecular engineering and machine learning. Please contact us at careers@dogodan.com